Literature DB >> 23414986

Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer.

Masatsugu Hamaji1, Mark S Allen, Stephen D Cassivi, Claude Deschamps, Francis C Nichols, Dennis A Wigle, K Robert Shen.   

Abstract

OBJECTIVE: To clarify the perioperative and oncologic outcome of pulmonary resection for a metachronous second primary lung cancer (MSPLC) following resection of an initial non-small cell lung cancer (NSCLC).
METHODS: Retrospective chart review identified 161 patients (88 men and 73 women) with a median age of 70 years (range, 34-88 years) who underwent pulmonary resection for MSPLC between January 2000 and December 2009. Operative morbidity, mortality, and relevant factors were analyzed with χ(2) test or Fisher exact test and Mann-Whitney U test. Survival was analyzed with Kaplan-Meier and Cox proportional hazard method.
RESULTS: The median interval between the initial and subsequent resection for MSPLC was 42.7 months (range, 7-205 months). There was no operative mortality and postoperative complication rate was 29%. In multivariate analysis, ipsilateral operation (P = .0002) and a lower predicted preoperative percent forced expiratory volume in the first second (P = .0035) were significant risk factors for postoperative complications. Five-year overall survival rates after resection of the initial and second metachronous NSCLC were 87.4% and 60.8%, respectively. Significant negative long-term prognostic factors for survival following resection of a MSPLC in multivariate analysis were tumor size >2 cm (P = .003) and number of pack years of smoking (P = .005). Metastatic nodal disease (P = .19) or a sublobar resection (P = .17) were not associated with worse survival.
CONCLUSIONS: Surgical treatment of a MSPLC can be undertaken with 5-year survival rate of 60%. Expected operative morbidity and mortality are comparable to primary surgery. Tumors 2 cm or smaller are associated with improved survival and freedom from recurrence. Close long-term follow-up of patients who have undergone resection of NSCLC is recommended.
Copyright © 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23414986     DOI: 10.1016/j.jtcvs.2012.12.051

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  29 in total

1.  Cons: long-term CT-scan follow-up is not the standard of care in patients curatively treated for an early stage non-small cell lung cancer.

Authors:  Jan P van Meerbeeck; Halil Sirimsi
Journal:  Transl Lung Cancer Res       Date:  2015-08

Review 2.  Lung cancer: Biology and treatment options.

Authors:  Hassan Lemjabbar-Alaoui; Omer Ui Hassan; Yi-Wei Yang; Petra Buchanan
Journal:  Biochim Biophys Acta       Date:  2015-08-19

3.  Impact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors.

Authors:  Jyoti Malhotra; Salma K Jabbour; Sharon Pine
Journal:  Transl Lung Cancer Res       Date:  2019-12

4.  Metachronous second primary lung cancer surgically treated five years or more after the initial surgery.

Authors:  Satoshi Koezuka; Yoshinobu Hata; Hajime Otsuka; Takashi Makino; Naobumi Tochigi; Kazutoshi Shibuya; Akira Iyoda
Journal:  Mol Clin Oncol       Date:  2015-07-01

5.  Identification of the methylation of p14ARF promoter as a novel non-invasive biomarker for early detection of lung cancer.

Authors:  L Li; Y Shen; M Wang; D Tang; Y Luo; W Jiao; Z Wang; R Yang; K Tian
Journal:  Clin Transl Oncol       Date:  2013-10-24       Impact factor: 3.405

6.  Adjuvant vinorelbine and cisplatin after complete resection of stage II and III non-small cell lung cancer: long-term follow-up of our study of Japanese patients.

Authors:  Makoto Sonobe; Masatsugu Hamaji; Hideki Motoyama; Toshi Menju; Akihiro Aoyama; Toyofumi F Chen-Yoshikawa; Toshihiko Sato; Hiroshi Date
Journal:  Surg Today       Date:  2018-03-03       Impact factor: 2.549

7.  Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma.

Authors:  R Taylor Ripley; Robert R McMillan; Camelia S Sima; Saad M Hasan; Usman Ahmad; Feiran Lou; David R Jones; Valerie W Rusch; Nabil P Rizk; James Huang
Journal:  Ann Thorac Surg       Date:  2014-07-16       Impact factor: 4.330

8.  Prognostic Impact of Tumor Doubling Time in Patients with Metachronous Lung Cancer.

Authors:  Keisuke Asakura; Yukihiro Yoshida; Hiroyuki Sakurai; Kazuo Nakagawa; Noriko Motoi; Shun-Ichi Watanabe
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

Review 9.  Basic experiments of bioabsorbable materials in prevention of postoperative intrapleural adhesions following thoracotomy.

Authors:  Masatsugu Hamaji; Bryan M Burt; Hiroshi Date; Tatsuo Nakamura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-12-10

10.  More Frequent Surveillance Following Lung Cancer Resection Is Not Associated With Improved Survival: A Nationally Representative Cohort Study.

Authors:  Timothy L McMurry; George J Stukenborg; Larry G Kessler; Graham A Colditz; Melisa L Wong; Amanda B Francescatti; David R Jones; Jessica R Schumacher; Caprice C Greenberg; George J Chang; David P Winchester; Daniel P McKellar; Benjamin D Kozower
Journal:  Ann Surg       Date:  2018-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.